Reply letter to “response to article by Johnna Perdrizet et al.” by Gomez and colleagues

ABSTRACT

This communication seeks to address the questions and criticisms issued by Gomez and colleagues in their letter on our original study “Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.” Gomez and colleagues are concerned that the assumptions used in our model may have unintended negative impacts for Brazil decision-making and we intend to clarify any potential misinterpretation of our assessment.

Disclosure of potential conflicts of interest

This work was supported by Pfizer Inc. All authors are employees of Pfizer Inc and may hold stock or stock options. All authors approved the final version of this reply letter publication.

Additional information

Funding

Pfizer Inc. funded this reply letter publication.